BriaCell Therapeutics ( NASDAQ: $BCTX ) will present new data showing robust anti-cancer activity from its next-gen Bria-OTS+™ platform at SITC 2025. Backed by a $2M NCI award, BriaCell advances Bria-BRES+™ and Bria-PROS+™ toward clinical trials.
https://globenewswire.com/news-release/2025/1...odels.html
#BriaCellTherapeutics #BriaCellTx #BriaCell